E
Sell
5/31/2023Downgrade
Hillstream BioPharma, Inc. (HILS) was downgraded to E+ from D- on 5/31/2023 due to a decline in the total return index and volatility index.
D
Sell
3/20/2023Downgrade
Hillstream BioPharma, Inc. (HILS) was downgraded to D- from D on 3/20/2023 due to a large decline in the growth index and solvency index. The quick ratio declined from 10.6 to 5.69.
D
Sell
3/3/2023Upgraded
Hillstream BioPharma, Inc. (HILS) was upgraded to D from D- on 3/3/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/23/2023Upgraded
Hillstream BioPharma, Inc. (HILS) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Hillstream BioPharma, Inc. (HILS) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.1414 to -$0.1845, EBIT declined 29.97% from -$1.64M to -$2.13M, and the quick ratio declined from 12.72 to 10.6.
D
Sell
10/3/2022Upgraded
Hillstream BioPharma, Inc. (HILS) was upgraded to D- from E on 10/3/2022 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2783 to -$0.1414, and operating cash flow increased 17.18% from -$2.01M to -$1.66M.
E
Sell
7/1/2022Upgraded
Hillstream BioPharma, Inc. (HILS) was upgraded to E from E- on 7/1/2022 due to a significant increase in the solvency index. The quick ratio increased from 0 to 10.94.
E
Sell
4/18/2022None
Tharimmune, Inc. (THAR) was downgraded to E- from U on 04/18/2022.
